This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
Page 2 of 565

Roche, Exelixis Skin Cancer Drug Delays Tumor Progression

By Adam Feuerstein

Roche intends to seek U.S. approval for cobimetinib later this year.

07:46AM 07/14/14

14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014

By Adam Feuerstein

Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.

11:54AM 07/10/14

Latest Sarepta Study Update Shows Greater Decline in Walking Ability

By Adam Feuerstein

Even with greater decline in walk performance after almost three years, Duchenne boys treated with eteplirsen are still benefiting from treatment, Sarepta says.

08:31AM 07/10/14

Radient Pharma: RIP

By Adam Feuerstein

The SEC halts trading in Radient Pharmaceuticals.

09:52AM 07/08/14

Provectus Admits Cash Running Low, Financing Coming Soon

By Adam Feuerstein

Provectus Biopharmaceuticals issued a "CEO Letter" Tuesday regurgitating all the recent spin and ridiculously unrealistic talking points about the company's experimental (but already obsolete) melanoma therapy PV-10.

09:14AM 07/08/14

Sarepta's Monday Selloff on New (Old) Worries Addressed

By Adam Feuerstein

Sarepta is selling off Monday on new worries about eteplirsen efficacy. Of course, these are really just old worries, recycled.

02:49PM 07/07/14

Arena CEO Dumps Stock as Share Price, Investor Confidence Slide

By Adam Feuerstein

Lief's $1.3 million sale of Arena shares was disclosed in an SEC filing last week.

11:23AM 07/07/14

Ampio Expects Investors to Wear Beer Goggles Before Reading Eye-Drug Press Release

By Adam Feuerstein

The hip waders I normally wear for protection from biotech bullshit aren't tall enough to wade through Ampio's current press release. I need a full haz-mat suit.

01:05PM 06/25/14

Mad About Missing Vertex Pharma's Big Move? Don't Be, The Stock Is Still Undervalued

By Adam Feuerstein

Investors aren't yet recognizing Vertex's ability to develop triple-combo therapies for hardest-to-treat cystic fibrosis patients.

11:26AM 06/25/14

Ohr Pharma Applies a Ton of Lipstick to Squalamine Pig

By Adam Feuerstein

A phase II study of Squalamine in wet age-related macular degeneration bombed badly.

12:07PM 06/24/14

Page 2 of 565

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,083.80 -2.83 -0.02%
S&P 500 1,987.96 +0.95 0.05%
NASDAQ 4,472.1080 -1.5890 -0.04%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs